Effects and metabolism of steroid hormones in human neuroblastoma cells

Steroids

Volumn 63, Issue 5-6, 1998, Pages 257-262

  Maggi, Roberto ^a   Poletti, Angelo ^a   Casulari, Luiz A ^a   Pimpinelli, Federica ^a   Piva, Flavio ^a   Zanisi, Maria R ^a   Martini, Luciano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

5 reductase; Antagonist; Cell culture; Metabolism; Neuroblastoma; Neuron; Progesterone; Proliferation; Testosterone

Indexed keywords

DEXAMETHASONE; MIFEPRISTONE; PROGESTERONE; STEROID 5ALPHA REDUCTASE; STEROID HORMONE; TESTOSTERONE;

CANCER CELL CULTURE; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DOSE RESPONSE; HORMONE METABOLISM; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; STEROID METABOLISM;

CELL DIVISION; CENTRAL NERVOUS SYSTEM; HUMANS; NEUROBLASTOMA; PROGESTERONE; TESTOSTERONE; TUMOR CELLS, CULTURED;

EID: 0032076305     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(98)00038-5     Document Type: Conference Paper

References (47)

1. 1. Grisoni R (1973). I tumori del sistema nervoso periferico e vegetative. In: Bucalossi P, Veronesi U (eds), Trattato di oncologia clinica. Casa Editrice Ambrosiana, Milano, Italy, pp. 2407-2422.
2. 2. Cooper MJ, Hutchins GM, Cohen PS, Helman LJ, Mennie RJ, Israel MA (1989). Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. Cell Growth Differ 3:149-159.
3. 3. Påhlman S, Mamaeva S, Meyerson G, Mattsson M E, Bjelfman C, Ortoft E, Hammerling U (1990). Human neuroblastoma cells in culture: A model for neuronal cell differentiation and function. Acta Physiol Scand Suppl 592:25-37.
4. 4. Påhlman S, Ruusala A-I, Abrahamsson L, Odelstad L, Nilsson K (1983). Kinetics and concentration effects of TPA-induced differentiation of cultured human neuroblastoma cells. Cell Differ 12: 165-170.
5. 5. Sadée W, Yu VC, Richards ML, Preis PN, Schwab MR, Brodsky FM, Biedler JL (1987). Expression of neurotransmitter receptors and myc protooncogenes in subclones of human neuroblastoma cell line. Cancer Res 47:5207-5212.
6. 6. Ciccarone V, Spengler B A, Meyers M B, Biedler J L, Ross RA (1989). Phenotypic diversification in human neuroblastoma cells: Expression of distinct neural crest lineages. Cancer Res 49:219-225.
7. 7. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS (1978). Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38:3751-3757.
8. 3H]pirenzepine binding associated with hydrolysis of phosphatidy-linositols J Neurochem 50:1513-1521.
9. 9. Mei L, Roeske WR, Yamamura H (1989). The coupling of muscarinic receptors to hydrolysis of inositol lipids in human neuroblastoma SH-SY5Y cells. Brain Res 504:7-14.
10. 10. Biedler JL, Helson L, Spengler BA (1973). Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33:2643-2652.
11. 11. Påhlman S, Ruusala A-I, Abrahamsson L, Mattsson MEK, Esscher T (1984). Retinoic acid-induced differentiation of cultured human neuroblastoma cells: A comparison with phorbol ester-induced differentiation. Cell Differ 14:135-144.
12. 12. McEwen B (1991). Steroid hormones are multifunctional messengers to the brain. Trends Endocrinol Metab 1:62-67.
13. 13. Ratka A, Hochhaus G, Wissler RN, Simpkins JW (1991). cAMP accumulation in opioid-sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone. Mol Cell Endocrinol 78: 155-162.
14. 14. Ferreira A, Caceres A (1991). Estrogen-enhanced neurite growth. Evidence for a selective induction of tau and stable microtubules. J Neurosci 11:392-400.
15. 15. Frankfurt M, Gould E, Woolley CS, McEwen BS (1990). Gonadal steroids modify dendritic spine density in ventromedial, hypothalamic neurons. A Golgi study in the adult rat. Neuroendocrinology 51:530-535.
16. 16. Ma ZQ, Spreafico E, Pollio G, Santagati S, Conti E, Cattaneo E, Maggi A (1993). Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc Natl Acad Sci USA 90:3740-3744.
17. 17. Agrati P, Ma ZQ, Patrone C, Picotti GB, Pellicciari C, Bondiolotti G, Bottone G, Maggi A (1997). Dopaminergic phenotype induced by oestrogens in a human neuroblastoma cell line. Eur J Neurosci 9:1008-1016.
18. 18. Maggi R, Pimpinelli F, Ma ZQ, Martini L, Maggi A (1994). Estradiol modulation of opioid receptors in estrogen-responsive human neuroblastoma cells (SK-ER3). Abs. IX Int Congr on Hormonal Steroids, Dallas, p.53.
19. 19. Garnier M, Di Lorenzo D, Albertini A, Maggi A (1997). Identification of estrogen-responsive genes in neuroblastoma SK-ER3 cells. J Neurosci 17:4591-4599.
20. 20. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM (1997). Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 138:4030-4033.
21. 21. Green PS, Gridley KE, Simpkins JW (1996). Estradiol protect against β-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 218:165-168.
22. 22. Celotti F, Melcangi RC, Martini L (1992). The 5α-reductase in the brain: molecular aspects and relation to brain function. Front Neuroendocrinol 13:163-215.
23. 23. Melcangi RC, Maggi R, Martini L (1993). Testosterone and progesterone metabolism in the human neuroblastoma cell line SH-SY5Y. J Steroid Biochem Mol Biol 46:811-818.
24. 24. Andersson S, Russell DW (1990). Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA 87:3640-3644.
25. 25. Michalek AM, Buck GM, Nasca PC, Freedman AN, Baptiste MS, Mahoney MC (1996). Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol 996-1001.
26. 26. Mandel M, Toren A, Rechavi G, Dor J, Ben-Bassat I, Neumann Y (1994). Hormonal treatment in pregnancy: A possible risk factor for neuroblastoma. Med Pediatr Oncol 23:133-135.
27. 27. Carmichael J, DeGraff W, Gazdar A, Minna J, Mitchell J (1987). Evaluation of a tetrazolium-based semi-automatic colorimetric assay: Assessment of chemosensitivity. Cancer Res 47:936-942.
28. 28. Baulieu E-E (1991). The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications. Endocrinol Metab Clin North Am 20:873-878.
29. 29. Taylor JA, Forsyth IA, Wang M-W (1996). Activity of progesterone and anti-progestins in a rat mammary primary cell culture system. J Steroid Biochem Mol Biol 58:117-121.
30. 30. Antonakis N, Markogiannakis E, Theodoropoulou M, Georgoulias V, Stournaras C, Gravanis A (1991). The antiglucocorticoid RU486 down-regulates the expression of interleukin-2 (IL-2) receptors in normal human lymphocytes. J Steroid Biochem Mol Biol 39:929-934.
31. 31. van Voorhis BJ, Anderson DJ, Hill JA (1989). The effects of RU486 on immune function and steroid-induced immunosuppression in vitro. J Clin Endocrinol Metab 69:1195-1199.
32. 32. Bardon S, Vignon F, Montcourrier P, Rochefort H (1987). Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47:1441-1448.
33. 33. Klijn JGM, Setyono-Han B, Sander HJ, Lamberts SWJ, de Jong FH, Deckers GH, Foekens JA (1994). Pre-clinical and clinical treatment of breast cancer with antiprogestins. Hum Reprod 9:181-189.
34. 34. Hurd C, Khattree N, Alban P, Nag K, Jhanwar SC, Dinda S, Moudgil VK (1995). Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J Biol Chem 270:28507-28510.
35. 35. Müller-Holzner E, Marth C, Zeimet AG, Hofstädter F, Daxenbichler G (1996). Effects of sex-and glucocorticoid steroids on breast cancer cells grown as either multicellular tumor spheroids or monolayers. J Steroid Biochem Mol Biol 58:13-19.
36. 36. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T (1994). Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 80:527-534.
37. 37. Olson JJ, Beck DW, Schlechte J, Loh P-M (1986). Hormonal manipulation of meningiomas in vitro. J Neurosurg 65:99-107.
38. 38. Pinski J, Halmos G, Shirahige Y, Wittliff JL, Schally AV (1993). Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486. J Clin Endocrinol Metab 77:1388-1392.
39. 39. Chasserot Golaz S, Schuster C, Dietrich JB, Beck G, Lawrence DA (1988). Antagonistic action of RU38486 on the activity os transforming growth factor-beta in fibroblasts and lymphoma cells. J Steroid Biochem 30:381-385.
40. 40. Chasserot Golaz S, Beck G (1988). Inhibition of hepatoma cell growth by a steroid anti-hormone. Cancer Res 41:333-343.
41. 41. Grunberg S, Weiss M, Spitz I, Ahmadi J, Sadun A, Russel CA, Lucci L, Stevenson LL (1991). Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861-866.
42. 42. Haak HR, De Keizer RJ, Hagenouw-Taal JC, Van Seters AP, Vielvoye GJ, Van Dulken H (1990). Successful mifepristone treatment of recurrent, inoperable meningioma. Lancet 1:124-127.
43. 43. Lamberts SWJ, Tanghe HLJ, Avezaat CJJ, Braakman A, Wijngaarde R, Koper JW, de Jong F (1992). Mifespritone (RU486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55:486-490.
44. 44. Horwitz KB (1992). The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer ? Endocr Rev 13:146-163.
45. 45. Maggi R, Pimpinelli F, Casulari LA, Piva F, Martini L (1996). Antiprogestins inhibit the binding of opioids to m receptors in nervous membrane preparations. Eur J Pharmacol 301:169-177.
46. 46. Liu JH, Garzo VG, Yen SS (1988). Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. Fertil Steril 50:245-249.
47. 47. Lahteenmaki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L, Luukkainen T (1987). Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 27:859-863.